Related by context. All words. (Click for frequent words.) 76 bladder ovarian 76 ovarian breast 74 lung pancreatic 74 colorectal lung 73 pancreatic prostate 73 breast endometrial 72 ovarian prostate 72 metastatic bladder 72 prostate pancreatic 72 colorectal gastric 72 hormone receptor negative 72 ovarian colon 72 unresectable tumors 72 pancreatic lung 71 ovarian lung 71 leukemia multiple myeloma 71 bladder cancers 71 metastatic pancreatic 71 ovarian endometrial 70 bladder prostate 70 metastatic colorectal 70 pancreatic ovarian 70 Medullary thyroid cancer 70 Basal cell 70 neuroendocrine cancers 70 invasive lobular 69 deCODE ProstateCancer TM 69 essential thrombocythemia ET 69 ErbB2 positive 69 ovarian pancreatic 69 pancreatic colon 69 breast ovary 69 skeletal metastases 69 untreated metastatic pancreatic 68 hormone refractory prostate 68 colorectal ovarian 68 Squamous cell 68 pancreatic adenocarcinoma 68 gastric pancreatic 68 benign neoplasms 68 uterine ovarian 68 Colon polyps 68 carcinoma HCC 68 metastatic renal 68 alpha1 antitrypsin deficiency 68 smoldering myeloma 68 Squamous 68 papillary renal cell carcinoma 67 epithelial cancers 67 Chronic lymphocytic leukemia 67 kidney urologic 67 nonmetastatic 67 colorectal carcinoma 67 CYT# potent vascular disrupting 67 oligodendrogliomas 67 basal cell carcinoma squamous 67 nonsmall cell lung cancer 67 T1c 67 recurrent metastatic 67 leukemia lymphomas 67 lung carcinomas 67 Papillary 67 commercialize deforolimus 67 cervical prostate 67 BRAF mutant 67 lung ovary 67 gastric cancers 67 ovarian colorectal 67 metastatic gastric 67 cervical breast 67 pancreatic bladder 67 lung esophageal 67 melanoma ovarian 66 precursor lesions 66 liver colon rectal 66 carcinoid 66 malignant cancerous 66 pancreatic endocrine 66 TTR amyloidosis 66 renal cell carcinomas 66 nonmelanoma 66 endometrial breast 66 LungAlert TM 66 colorectal liver 66 pancreatic gastric 66 recurrent NSCLC 66 hematological diseases 66 prostate colon 66 cirrhosis liver failure 66 lymphomas leukemias 66 neoplasias 66 demonstrated antitumor activity 66 prostate carcinoma 66 malignant lymphoma 66 prostate carcinomas 66 epithelial tumors 66 HER2 amplified 66 ductal adenocarcinoma 66 lymphoid malignancies 66 basal cell skin 66 situ LCIS 66 LHRH receptor positive 66 colorectal bladder 66 breast uterine 66 colorectal prostate 66 metastatic liver 65 pancreatic colorectal 65 lymphoproliferative disorders 65 malignant pleural mesothelioma 65 colon esophageal 65 CTAP# Capsules 65 Her2 positive 65 deCODE BreastCancer 65 esophageal gastric 65 peritoneal carcinomatosis 65 immunodeficiency disorders 65 BCG refractory 65 MAGE A3 65 alpha1 antitrypsin AAT deficiency 65 subependymal giant cell 65 prostate ovarian 65 Carcinoid tumors 65 testicular cancers 65 castration resistant hormone refractory 65 sarcoma melanoma 65 lobular carcinoma 65 ovarian esophageal 65 stage IIIb IV 65 lung colon 65 basal cell carcinoma BCC 65 adrenocortical cancer 65 bladder colon 65 lung colorectal 65 squamous cell lung cancer 65 prostate bladder 65 castrate resistant 65 lymphoma subtypes 65 sarcomatoid 65 adenomatous 65 Basal Cell 65 completely resected 65 cervical ovarian 65 K ras mutations 65 brain metastases originating 64 relapsed leukemia 64 mouse xenograft models 64 colorectal pancreatic 64 osteosarcomas 64 colon pancreas 64 hepatocellular carcinoma liver 64 cervical uterine 64 advanced hepatocellular carcinoma 64 recurrent glioblastoma multiforme 64 ductal carcinomas 64 Kit CD# positive 64 autosomal dominant polycystic kidney 64 histologies 64 ovarian uterine 64 testicular germ cell 64 underwent surgical resection 64 resistant hormone refractory 64 metastatic HER2 positive 64 pituitary adenomas 64 HER2 positive metastatic 64 tongue mouth pharynx 64 histological subtypes 64 muscular dystrophy cystic fibrosis 64 superficial basal cell carcinoma 64 neovasculature 64 BRCA deficient 64 cisplatin resistant 64 non resectable metastatic 64 refractory metastatic 64 mycosis fungoides 64 refractory chronic lymphocytic 64 non resectable 64 radiolabeled TM# 64 tuberous sclerosis TS 64 KRAS mutant 64 papillary carcinoma 64 urothelial carcinoma 64 substantially excreted 64 Anaplastic 64 biliary cancer 64 haematologic malignancies 64 ductal breast cancer 64 endometrial ovarian 64 gastrointestinal stromal 64 myelodysplastic myeloproliferative diseases 64 lung adenocarcinoma 64 benign prostatic hyperplasia enlarged 64 tumors GIST 64 pulmonary metastases 64 epithelial ovarian 64 surgically resectable 64 colon ovarian 64 AstraZeneca Arimidex 64 BRAF mutated 64 radiation chemoradiation 64 Peginterferon alfa 2b 64 ADPKD 64 HER2 positive breast 64 invasive ductal 64 peritoneal cancer 64 A1PI 64 neoplastic 64 hyperplasia BPH 64 immunological diseases 64 hepatocellular cancer 64 dysplastic lesions caused 64 metastatic neuroendocrine tumors 64 adenocarcinomas 64 Menopausal hormone therapy 64 lymphoma multiple myeloma 63 nodal metastasis 63 endometrial cancers 63 Solazed TM 63 bone marrow lymph nodes 63 leukemias lymphomas 63 HER2 positive cancers 63 malignant pleural mesothelioma MPM 63 metastatic renal cell 63 esophagus colon 63 Leukemias 63 p# biomarker 63 gefitinib Iressa 63 neovascular diseases 63 deCODE AF TM 63 drug GAP #B# 63 advanced adenomas 63 lymphoproliferative diseases 63 gastric adenocarcinoma 63 colorectum 63 Endometrial 63 antibody MAb 63 ribonucleotide reductase clinically validated 63 HNSCC 63 antiproliferative effects 63 Shark cartilage 63 situ CIS 63 hormonally sensitive 63 malignant ascites 63 Acute myeloid leukemia 63 ipsilateral breast 63 ZACTIMA 63 pancreas esophagus 63 dasatinib Sprycel 63 anti PlGF 63 NMIBC 63 INSPIRE Trial Phase III 63 relapsed acute lymphoblastic 63 prostate lung 63 gastrointestinal malignancies 63 BRCA1 BRCA2 63 carcinoid tumors 63 mutated K ras 63 histologically confirmed 63 gastrointestinal stromal tumors GISTs 63 myeloproliferative disorders 63 advanced medullary thyroid 63 Hepatocellular 63 acid phosphatase PAP 63 bile duct cancers 63 medullary thyroid 63 pancreatic islet cell 63 ovarian cervical 63 cause mesothelioma asbestosis 63 MGd 63 colorectal adenocarcinoma 63 genitourinary cancers 63 myelomas 63 metastatic carcinoma 63 Myelodysplastic syndromes MDS 63 leukemia myeloma 63 pelvic malignancies 63 breast colorectal 63 node metastasis 63 intestinal polyps 63 Colorectal cancer CRC 63 Uterine cancer 63 locoregional recurrence 63 gene BRCA2 63 serous ovarian cancer 63 gastric carcinoma 63 Alessandro Riva 63 cervical carcinoma 63 Cholangiocarcinoma 63 acute myeloid 63 oral clodronate 63 Ph + acute lymphoblastic 63 lymphoma leukemia 63 erlotinib Tarceva ® 63 HER2 positive metastatic breast 63 hormone refractory metastatic prostate 63 pediatric acute lymphoblastic 63 Evoltra ® 63 Prednisone Against Refractory 63 Sezary syndrome 63 haematological cancers 63 histologic subtype 63 DCVax R 63 Ribavirin causes 63 cancerous enlargement 63 PROLARIS 63 tumor xenograft models 63 colon rectum breast 63 metastatic malignant 63 colon lung 62 colon pancreatic 62 neuroendocrine carcinoma 62 metastatic lymph nodes 62 lung adenocarcinomas 62 cervical lymph nodes 62 squamous non 62 polyps growths 62 visit www.rtanswers.org 62 MAGE A3 protein 62 neuroendocrine tumors 62 chronic lymphocytic 62 AML acute myeloid 62 hepatic liver 62 thalidomide Thalomid 62 metastatic adenocarcinoma 62 invasive lobular carcinoma 62 sorafenib tablets 62 Estrogen receptor positive 62 premalignant lesion 62 Arimidex anastrozole 62 squamous cell carcinoma SCC 62 cervical lymph node 62 fallopian tube cancers 62 Endometrial cancer 62 oral squamous cell 62 chemo resistant 62 unresectable liver cancer 62 chemosensitizer 62 colon prostate 62 whose tumors overexpress 62 metastatic androgen independent 62 KRAS oncogene 62 HBeAg negative 62 Insegia 62 metachronous 62 post transplant lymphoproliferative 62 molecular diagnostic assay 62 LymphoStat B belimumab 62 leukemia lymphoma multiple myeloma 62 Mitomycin C 62 myeloproliferative neoplasms 62 nonalcoholic steatohepatitis NASH 62 hypervascular tumors 62 GISTs 62 Acute myeloid leukemia AML 62 FUSILEV enhances 62 bladder cervix 62 trastuzumab Herceptin R 62 Benign breast 62 eIF 4E 62 malignant neoplasm 62 gastric corpus 62 transplantation HCT 62 Bayer Nexavar 62 TMPRSS2 ERG 62 breast carcinomas 62 mutated KRAS 62 prostate adenocarcinoma 62 Combination REOLYSIN R 62 mucinous 62 esophagogastric junction 62 Naive Patients 62 metastatic medullary thyroid 62 candidates Azedra TM 62 tumor metastases 62 hematologic disorders 62 relapsed MM 62 malignant prostate 62 stage IIIA 62 osteolytic bone disease 62 Epigenomics proprietary 62 include ColorectAlert TM 62 leukaemias 62 OVARIAN 62 neurofibromas 62 potent antiproliferative 62 vitro pharmacology 62 KRAS mutated 62 gemcitabine chemotherapy 62 brivanib 62 breast ovarian 62 Amgen Neulasta R 62 molecular abnormalities 62 histone deacetylase inhibitor 62 Surgical resection 62 Chronic lymphocytic leukemia CLL 62 undergone radical prostatectomy 62 leiomyoma 62 novel VDA molecule 62 Vandetanib 62 Adjuvant chemotherapy 62 Radical prostatectomy 62 Fludara ® 62 Li Fraumeni 62 vaginal lesions 62 treating sarcoma testicular 62 Philadelphia Chromosome Positive 62 Vicinium TM 62 atypical hyperplasia 62 colorectal breast 62 squamous cell cancer 62 HER2 neu 62 hypercholesterolemia liver 62 anaplastic astrocytoma AA 61 RhuDex R 61 Septin9 61 tested eribulin 61 myelofibrosis polycythemia vera 61 gynecologic malignancy 61 including eniluracil ADH 61 transthyretin amyloidosis 61 oropharyngeal candidiasis OPC 61 advanced HER2 positive 61 MCSP respectively 61 GVAX Immunotherapy 61 cholangiocarcinoma 61 Lewy bodies DLB 61 Wilms tumors 61 BRCA1 mutation carriers 61 lung ovarian 61 TNF blocker therapy 61 KRAS mutations occur 61 malignant lymphomas 61 Monoclonal antibody 61 differentiated thyroid 61 hepatocellular carcinoma HCC 61 Renal cell carcinoma 61 targeted radiotherapeutic 61 kidney fibrosis 61 oncological indications 61 treating cancerous tumors 61 contralateral breast 61 HIV HCV coinfected 61 chemoresistant 61 Adenocarcinoma 61 haematologic 61 hormonally responsive 61 colon breast 61 TRAIL R1 61 Genasense ® 61 cetuximab Erbitux 61 metastatic breast 61 taxane therapy 61 Waldenstrom macroglobulinemia 61 leukemia AML 61 Vidaza ® 61 CDK cyclin dependent 61 Brain metastases 61 Tesmilifene 61 IMC #B 61 medically inoperable 61 ovary uterus 61 radiosensitive 61 hepatitis C viral infection 61 non polyposis colorectal 61 Velcade bortezomib 61 lymphoid tumors 61 molecular subtypes 61 Roche Herceptin 61 diffuse gastric 61 endometrial hyperplasia 61 pheochromocytoma 61 vinca alkaloid 61 nonmelanoma skin cancers 61 refractory Hodgkin 61 malignant ovarian 61 Chronic Myelogenous Leukemia CML 61 Selective Internal 61 nasopharyngeal carcinoma 61 mitoxantrone plus 61 metastatic melanomas 61 precancerous condition 61 EGFR mutation positive 61 chemotherapy cisplatin 61 trastuzumab Herceptin ® 61 fallopian tube carcinoma 61 TTR gene 61 metastatic HER2 negative 61 endocrine therapies 61 HER2 expression 61 castration resistant 61 Leydig cell 61 syngeneic 61 bacterial biothreat agents 61 metaplasia 61 Soft tissue sarcomas 61 Squamous Cell 61 cystic fibrosis chronic pancreatitis 61 recurrent epithelial ovarian 61 lupus multiple sclerosis 61 lung prostate 61 intra arterial chemotherapy 61 Adjuvant Treatment 61 ovarian carcinoma 61 benign uterine 61 non hodgkin lymphoma 61 lobular carcinomas 61 Epidermal Growth Factor Receptor 61 cellular immunotherapy 61 lobular cancer 61 Hurthle cell 61 Chronic Lymphocytic Leukemia CLL 61 cervix colon 61 Cotara ® 61 sunitinib Sutent 61 methylation markers 61 squamous cell 61 malignant fibrous histiocytoma 61 allogeneic hematopoietic stem cell 61 pT3 61 hypermethylated 61 seminomas 61 Patients Treated With 61 CLL SLL 61 hematological disorders 61 Proxinium TM 61 prostate breast 61 hormone refractory 61 neoplastic diseases 61 hepatic lesions 61 Systemic lupus erythematosus 61 malignant brain 61 humanised monoclonal antibody 61 hepatocellular carcinomas 61 Aflibercept 61 thymectomy 61 EGFR mutant 61 Nexavar sorafenib 61 advanced pancreatic neuroendocrine 61 anti EGFR antibody 61 hepatorenal syndrome 61 mutated p# 61 vinca alkaloids 61 finasteride Proscar 61 Human papillomaviruses 61 polycythemia vera essential thrombocythemia 61 pilocytic astrocytomas 61 adjuvant radiotherapy 61 cell acute lymphoblastic 61 benign noncancerous 61 benign ovarian 61 hepatic renal 61 Lymphocytic 61 lymph node enlargement 61 coagulation disorders 61 CIN2 + 61 Hodgkin lymphoma HL 61 palliative radiotherapy 61 breast carcinoma 61 oral picoplatin 61 BRAF V# mutation 61 immunohistochemical staining 61 MAGE A3 ASCI 61 BRAF V#E mutation 61 B Cell Lymphoma 61 Relapsed Refractory 61 squamous 61 stage IIIB IV 61 Cojocaru correspondent 61 fluoropyrimidine 61 Acute Exacerbations 61 proliferative disorders 61 ABCB1 61 thrombo embolic 61 sinonasal 61 progesterone receptor negative 61 advanced epithelial ovarian 61 underwent resection 61 astrocytomas 61 carcinoids 61 Immunotherapeutic 61 IgG1 monoclonal antibody 61 pancreatic carcinoma 61 prostate cancer CaP 60 follicular thyroid cancer 60 HER2 receptor 60 Phase #b/#a clinical 60 pancreatic neuroendocrine 60 Pemetrexed 60 metastatic basal cell 60 hypereosinophilic syndrome 60 Relapsing remitting MS 60 soluble tumor necrosis 60 undergoing hematopoietic stem 60 cause cardiac channelopathies 60 Lung transplantation 60 leiomyomas 60 androgen receptor antagonist 60 localized prostate 60 cutaneous melanoma 60 cisplatin gemcitabine 60 Glioblastoma Multiforme 60 Gliomas 60 anemias 60 PKCi 60 Metastases 60 gastrointestinal cancers 60 grade cervical intraepithelial 60 Renal Cell Carcinoma RCC 60 gastrointestinal stromal tumor 60 Campath alemtuzumab 60 hamartomas 60 clinically localized prostate 60 Lymphoid 60 metastatic prostate 60 pulmonary metastasis 60 gemcitabine carboplatin 60 GW# [003] 60 BRCA2 gene mutation 60 neuroblastoma tumors 60 Non Hodgkin 60 thetreatment 60 Metastatic breast cancer 60 urothelial cancer 60 SSc 60 refractory colorectal cancer 60 papillary 60 radiotherapy RT 60 oncolytic virus therapies 60 malignant polyps 60 interleukin IL -# 60 Acute myelogenous leukemia 60 ependymomas 60 KRAS mutations 60 Metastatic 60 Idiopathic pulmonary fibrosis 60 Glioblastoma multiforme GBM 60 MKC# MT 60 surgically resected 60 advanced adenoma 60 Hematologic 60 colon rectal 60 efaproxiral 60 BCG refractory carcinoma 60 previously untreated follicular 60 BRAF V#E 60 Carcinomas 60 IMA# 60 dysplastic nevi 60 pT2 60 OncoVex 60 invasive ductal carcinoma 60 Virulizin ® 60 e antigen HBeAg 60 prostate colorectal 60 Platinum Resistant Ovarian 60 liposomal amphotericin B 60 gastrointestinal stromal tumors 60 Adjuvant Chemotherapy 60 multiforme 60 histological subtype 60 underwent prostate biopsy 60 antimitotic 60 CDH1 60 ZACTIMA TM ZD# 60 hematopoietic malignancies 60 esophagus pancreas 60 castrate resistant prostate cancer 60 penile cancers 60 GSTP1 60 HRPC ovarian cancer 60 gemcitabine Gemzar 60 galiximab 60 idiopathic PAH 60 PCA3 gene 60 idiotype protein 60 OnDose TM 60 gastric cardia 60 stage IIIB 60 recurrent ovarian 60 systemic amyloidosis 60 myeloproliferative diseases 60 dacarbazine DTIC 60 Neo Bladder Augment 60 hepatocellular 60 Familial Adenomatous Polyposis 60 included exfoliative dermatitis 60 uterine cervical 60 multiple myeloma MM 60 Chronic myeloid leukemia 60 androgen receptor AR 60 Taxotere docetaxel 60 GPC5 60 sodium thiosulfate STS 60 evaluating tivozanib 60 non squamous 60 humanised antibody 60 embryonal rhabdomyosarcoma 60 hormone receptor status 60 Anthracycline 60 paragangliomas 60 unresectable locally advanced 60 untreated metastatic melanoma 60 prostate testicular 60 follicular Non Hodgkin 60 PROSTVAC VF 60 promoter hypermethylation 60 Phase #/#a trial 60 parathyroid carcinoma 60 Temsirolimus 60 treat benign prostatic 60 nonalcoholic steatohepatitis 60 metastatic GIST 60 MyVax R 60 Pfizer Camptosar 60 gastroesophageal junction 60 pemphigus vulgaris 60 intracranial tumors 60 mesangial 60 CTL epitopes 60 oesophageal adenocarcinoma 60 GBMs 60 chronic eosinophilic leukemia 60 signal transduction inhibitors 60 aerodigestive tract 60 cell carcinoma RCC 60 leiomyosarcoma 60 radiotherapeutic 60 intestinal metaplasia 60 AVASTIN 60 AML MDS 60 cervix vagina 60 T1a 60 thalassemia sickle cell 60 precancerous cervical 60 incontinence erectile dysfunction 60 endometrial kidney 60 immunocompetent 60 adenomatous polyps 60 hA# 60 adjuvant cisplatin 60 Hepatocellular Carcinoma HCC 60 imatinib Gleevec ® 60 ductal cancer 60 MLL AF9 60 Gleevec resistant 60 Epstein Barr virus EBV 60 Adenomas 60 PARP inhibition 60 Septin9 biomarker 60 lymphoid organs 60 chronic myocardial ischemia 60 anastrazole 60 Nonalcoholic fatty liver 60 BRAF gene mutations 60 PLX STROKE targeting 60 thymoma 60 uterine cervix 60 YONDELIS R 60 interferon gamma 1b 60 chronically immunosuppressed solid 60 cancer mCRC 60 biliary tract cancer 60 SIR Spheres 60 targeting miR 60 papillary thyroid carcinoma 60 metaglidasen 59 abnormal p# 59 IDH1 mutations 59 diseases fat malabsorption 59 erythematosus 59 cells overexpressing 59 Initiate Clinical Trial 59 Bleomycin 59 hereditary predisposition 59 metastatic hormone refractory 59 PSMA ADC 59 MCF7 59 mutated KRAS gene 59 advanced malignant hepatic 59 hyperphenylalaninemia HPA due 59 temozolomide Temodar 59 seminoma 59 novel therapeutic antibodies 59 YONDELIS 59 Advanced Renal Cell 59 humanized therapeutic 59 RET PTC rearrangements 59 anti angiogenic agents 59 products MKC# PP 59 colorectal adenoma 59 colorectal metastases 59 cisplatin chemotherapy 59 Bayer HealthCare Onyx Pharmaceuticals 59 Paraplatin ® 59 humanized monoclonal antibodies 59 Cell Non Hodgkin 59 removed laparoscopically 59 docetaxel Taxotere R 59 rhabdoid 59 Basal cell carcinoma 59 relapsing remitting MS RRMS 59 MALT lymphoma 59 renal carcinoma 59 inhibit metastasis 59 squamous histology 59 Sudhir Agrawal D.Phil 59 pancreatic neuroendocrine tumors 59 deletion 5q 59 recurrent malignant glioma 59 HER2 ErbB2 59 receptor tyrosine kinase inhibitor 59 gastrin analogue TT 59 fibrocystic disease 59 Candida infection 59 colon carcinoma 59 carcinomas 59 NSCLC tumors 59 neoplastic lesions 59 AEG# 59 xenograft models 59 liposomal doxorubicin 59 BRCA2 carriers 59 radiosensitivity 59 ANCA associated 59 collagen vascular 59 basal epithelial 59 anaplastic 59 colorectal cancer CRC 59 Neuroendocrine tumors 59 cutaneous T 59 axillary lymph nodes 59 orchitis 59 thyroid carcinoma 59 HyperAcute 59 pancreatic cancers 59 invasive carcinoma 59 hPAM4 59 Shows Promise Against 59 pegylated liposomal doxorubicin 59 neoadjuvant treatment 59 Malignant Melanoma 59 supratentorial 59 radioimmunotherapy RIT 59 chronic thromboembolic pulmonary 59 antibody MT# 59 KRAS mutation 59 invasive carcinomas 59 stratifying patients 59 epithelial origin 59 chromophobe 59 polycystic kidneys 59 Hormone Refractory Prostate Cancer 59 Chronic pancreatitis 59 Myelodysplastic syndromes 59 trastuzumab Herceptin 59 patients undergoing CABG 59 monoclonal antibody conjugated 59 microsphere therapy 59 DNA methylation biomarkers 59 miRview ™ squamous 59 Quinamed 59 Trastuzumab DM1 59 multigene expression test 59 Soft Tissue Sarcoma 59 bronchogenic carcinoma 59 obstructive coronary 59 antisense inhibitors 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 acyclovir Lauriad R 59 advanced metastatic prostate 59 targets Galectin receptors 59 5 FU leucovorin 59 renal tumors 59 accumulate preferentially 59 stem cells CSCs 59 preoperative chemotherapy 59 node metastases 59 systemic autoimmune 59 refractory gastrointestinal stromal 59 ThermoDox R 59 Paraplatin ® carboplatin 59 Glioma 59 postoperative pathology 59 ER CHOP 59 preoperative staging 59 Immunohistochemical staining 59 Serostim ® 59 Thalomid ® 59 neoadjuvant setting 59 Rituxan rituximab 59 Crohn colitis 59 malignant pheochromocytoma 59 bowel cancers 59 alkylating 59 MEK inhibitors 59 latent celiac disease 59 prostate cancer PCa 59 tumor subtypes 59 treat musculoskeletal metabolic 59 pre malignant lesions 59 PARP inhibitor 59 Mesothelin 59 PGDH 59 allogeneic HSCT 59 bullous 59 IGF IR 59 Glioblastoma multiforme 59 Salvatore Glorioso mayor 59 urologic diseases 59 pheochromocytomas 59 taxane chemotherapy 59 faulty BRCA genes 59 mutated BRAF gene 59 sorafenib Nexavar 59 capecitabine Xeloda 59 hepatitis C HCV 59 receiving chemoradiation therapy 59 bladder tumors 59 secondary hyperparathyroidism 59 Prognostic factors 59 Chronic myeloid leukemia CML 59 docetaxel Taxotere ® 59 gemcitabine Gemzar ® 59 ara C 59 abnormal pap smears 59 Nexavar tablets 59 non mutated KRAS 59 paclitaxel Taxol ® 59 NOLVADEX 59 pancreatic ductal 59 Atypical Hemolytic Uremic Syndrome 59 tumor histology 59 KRAS wild 59 orthotopic model 59 RNAi therapeutic targeting 59 systemic anaplastic large 59 epithelioid 59 factor TNF receptor 59 prostate cancer CRPC 59 haematopoietic stem cell 59 Factor Receptor 59 transitional cell carcinoma 59 obstructive coronary artery 59 cyclin dependent kinase inhibitor 59 decompensated liver disease 59 spinal metastases 59 Factor VIIa 59 Cutaneous T 59 Amgen Neulasta ® 59 recurrent glioblastoma multiforme GBM 59 Trichomonas vaginalis 59 p# mutations 59 neoplastic cells 59 Epstein Barr Virus 59 HGS ETR1 mapatumumab 59 susceptibility loci 59 MYCN amplification 59 huC# DM4 59 CD# expressing 59 indications Dupuytren 59 Pleural mesothelioma 59 precancers 59 Chlamydia psittaci 59 SNT-MC#/idebenone 59 Apaziquone 59 Teverelix 59 Dendreon investigational 59 Gorlin syndrome 59 minimally symptomatic 59 beta islets 59 advanced metastatic renal 59 Antitumor Activity 59 hematopoietic disorders 59 malignant neoplasms 59 Brentuximab Vedotin SGN 59 biliary tract 59 liver scarring 59 chemoembolization 59 tumor nodules 59 Modrenal 59 essential thrombocythemia 59 esophageal cancers 59 Polycythemia vera 59 Stage IIIb 59 MTHFR 59 mTOR mammalian target 59 ALK inhibitors 59 preclinical xenograft models 59 colorectal 59 underwent radical prostatectomy 59 non alcoholic steatohepatitis 59 recurrent glioblastoma 59 precancerous tissues 58 relapsed acute myelogenous 58 cediranib 58 small lymphocytic lymphoma 58 refractory anaplastic astrocytoma 58 operable breast cancer 58 antihormonal therapy 58 extracapsular extension